Literature DB >> 33663052

Delirium caused by topical administration of cyclopentolate for cataract surgery in mild cognitive impairment due to Alzheimer's disease: A case report.

Yu Yong Shin1, Jin San Lee2, Key-Chung Park2, Hak Young Rhee3.   

Abstract

RATIONALES: Cholinergic modification by anticholinergic medication can produce adverse effects in central nervous system (CNS) and cyclopentolate is an antimuscarinic agent widely used for ophthalmologic management. We demonstrate a rare case of hyperactive delirium caused by topical administration of cyclopentolate in a patient with amnestic mild cognitive impairment (MCI) due to Alzheimer's disease (AD). PATIENT CONCERNS: A 74-year-old man showed acute confusion after preparation for cataract operation in day surgery clinic. The patient became confused and agitated after instillation of topical cyclopentolate drop into the eye and the symptoms persisted over several hours. DIAGNOSIS: Previously the patient had been diagnosed with amnestic MCI with the finding of bilateral medial temporal atrophy on brain magnetic resonance imaging. 18F-flutemetamol positron emission tomography scan demonstrated multifocal amyloid deposition in the brain.
INTERVENTIONS: The patient was closely observed with the supportive management. OUTCOMES: The patient began to recover 5 h after the onset of symptoms and the cognitive function was reverted to previous state within 24 h. LESSONS: It is well known that several drugs with anticholinergic effects used in perioperative periods make the patients susceptible to delirium, but even the topical administration of cyclopentolate for cataract surgery also produce adverse CNS effects in a vulnerable patient who is diagnosed with MCI due to AD in this case.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33663052      PMCID: PMC7909168          DOI: 10.1097/MD.0000000000024394

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  5 in total

1.  Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults.

Authors:  Shannon L Risacher; Brenna C McDonald; Eileen F Tallman; John D West; Martin R Farlow; Fredrick W Unverzagt; Sujuan Gao; Malaz Boustani; Paul K Crane; Ronald C Petersen; Clifford R Jack; William J Jagust; Paul S Aisen; Michael W Weiner; Andrew J Saykin
Journal:  JAMA Neurol       Date:  2016-06-01       Impact factor: 18.302

2.  Systemic and ocular absorption and antagonist activity of topically applied cyclopentolate in man.

Authors:  M Haaga; T Kaila; L Salminen; P Ylitalo
Journal:  Pharmacol Toxicol       Date:  1998-01

Review 3.  Acute psychotic reaction caused by topical cyclopentolate use for cycloplegic refraction before refractive surgery: case report and review of the literature.

Authors:  Alireza Mirshahi; Thomas Kohnen
Journal:  J Cataract Refract Surg       Date:  2003-05       Impact factor: 3.351

4.  Mental status changes induced by eye drops in dementia of the Alzheimer type.

Authors:  P F Reyes; B A Dwyer; R J Schwartzman; T Sacchetti
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-01       Impact factor: 10.154

Review 5.  Cholinergic deficiency hypothesis in delirium: a synthesis of current evidence.

Authors:  Tammy T Hshieh; Tamara G Fong; Edward R Marcantonio; Sharon K Inouye
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2008-07       Impact factor: 6.053

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.